107 related articles for article (PubMed ID: 1372881)
1. Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.
Fosså SD; Lehne G; Gunderson R; Hjelmaas U; Holdener EE
Int J Cancer; 1992 Apr; 50(6):868-70. PubMed ID: 1372881
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
Fosså SD; Gunderson R; Moe B
Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
[TBL] [Abstract][Full Text] [Related]
5. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
8. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K; Alm G
Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
[TBL] [Abstract][Full Text] [Related]
9. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial.
Steineck G; Strander H; Carbin BE; Borgström E; Wallin L; Achtnich U; Arvidsson A; Söderlund V; Näslund I; Esposti PL
Acta Oncol; 1990; 29(2):155-62. PubMed ID: 2185803
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
[TBL] [Abstract][Full Text] [Related]
11. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon-alpha 2b.
Tsavaris N; Baxevanis K; Kosmidis P; Papamichael M
Tumour Biol; 1995; 16(6):365-73. PubMed ID: 7569683
[TBL] [Abstract][Full Text] [Related]
13. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
14. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.
Schornagel JH; Verweij J; ten Bokkel Huinink WW; Klijn JG; de Mulder PH; Debruyne FM; van Deijk WA; Roozendaal K; Kok TC; Veenhof KH
J Urol; 1989 Aug; 142(2 Pt 1):253-6. PubMed ID: 2746739
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
17. Interferon as adjunctive treatment for non-metastatic renal cell carcinoma.
Takahashi S; Tanigawa T; Imagawa M; Mimata H; Nomura Y; Ogata J
Br J Urol; 1994 Jul; 74(1):11-4. PubMed ID: 8044505
[TBL] [Abstract][Full Text] [Related]
18. Treatment of renal cancer patients with gemcitabine (2',2'-difluorodeoxycytidine) and interferons: antitumor activity and toxicity.
Rohde D; Thiemann D; Wildberger J; Wolff J; Jakse G
Oncol Rep; 1998; 5(6):1555-60. PubMed ID: 9769405
[TBL] [Abstract][Full Text] [Related]
19. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
